DJIA 17,440.59 -127.94 -0.73%
NASDAQ 5,039.78 -48.85 -0.96%
S&P 500 2,067.64 -12.01 -0.58%
market minute promo

Geron Corp (NASDAQ: GERN)

4.09 -0.03 (-0.61%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GERN $4.09 -0.61%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.10
Previous Close $4.11
Daily Range $4.02 - $4.12
52-Week Range $1.76 - $4.67
Market Cap $645.8M
P/E Ratio -17.87
Dividend (Yield) $0.00 (0.0%)
Volume 2,170,505
Average Daily Volume 2,809,176
Current FY EPS -$0.07




Drug Makers

Geron Corp (GERN) Description

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. Website:

News & Commentary

3 Biotech Stocks That Could Double Before 2016

Here is a look at three small-cap biotech stocks with the potential to double within the next six months.

Geron's Second-Line Myelofibrosis Trial Offers Significant EPS Potential

Geron's Much Anticipated Imetelstat Phase 2 Study Grows To 50 Locations And Begins Enrollment

Orphan Drugs Series: Time From ODD To Market Approval

Geron (GERN) Is Today's Dead Cat Bounce Stock

3 Experimental Cancer Drugs Investors Should Be Closely Watching

Meet the drugs our experts believe have shown the most promising results in the race to cure cancer.

Geron (GERN) Highlighted As Weak On High Volume

Premarket Biotech Digest: Geron's Sharp Gain, Bayer Essure AEs, Juno Moves Higher

This Biotech Stock Has Jaw-Dropping Growth Potential

Geron Corp. is small-cap biotech with major growth potential.

Geron Is Ripe For A Short Squeeze

See More GERN News...

GERN's Top Competitors

GERN $4.09 (-0.61%)
Current stock: GERN
GILD $110.54 (-2.03%)
Current stock: GILD
AMGN $165.54 (4.38%)
Current stock: AMGN
BIIB $309.43 (3.13%)
Current stock: BIIB